tiprankstipranks
Trending News
More News >
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
US Market

Ultragenyx Pharmaceutical (RARE) Income Statement

Compare
1,087 Followers

Ultragenyx Pharmaceutical Income Statement

Last quarter (Q3 2025), Ultragenyx Pharmaceutical's total revenue was $159.93M, an increase of 14.65% from the same quarter last year. In Q3, Ultragenyx Pharmaceutical's net income was $-180.41M. See Ultragenyx Pharmaceutical’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 560.23M$ 434.25M$ 363.33M$ 351.41M$ 271.03M
Gross Profit
$ 483.50M$ 389.04M$ 335.01M$ 335.40M$ 264.90M
Operating Expenses
$ 1.02B$ 958.25M$ 983.93M$ 717.13M$ 595.02M
Depreciation and Amortization
$ 35.54M$ 26.01M$ 18.22M$ 13.24M$ 12.26M
EBITDA
$ -469.00M$ -516.45M$ -640.49M$ -410.32M$ -139.81M
Operating Income
$ -535.97M$ -569.21M$ -648.92M$ -381.74M$ -330.12M
Other Income/Expenses
$ -31.61M$ -39.26M$ -52.81M$ -71.24M$ 144.76M
Pretax Income
$ -567.59M$ -608.46M$ -701.73M$ -452.98M$ -185.36M
Net Income
$ -569.18M$ -606.64M$ -707.42M$ -454.02M$ -186.57M
Per Share Metrics
Basic EPS
$ -6.29$ -8.25$ -10.12$ -6.70$ -3.07
Diluted EPS
$ -6.29$ -8.25$ -10.12$ -6.70$ -3.07
Weighted Average Shares Outstanding
90.54M 73.54M 69.91M 67.80M 60.85M
Weighted Average Shares Outstanding (Diluted)
90.54M 73.54M 69.91M 67.80M 60.85M
Currency in USD

Ultragenyx Pharmaceutical Earnings and Revenue History